The Origin of Antibody Drug In Modern Time

In 1997, the FDA approved Rituximab for the treatment of B-cell lymphoma. This is a milestone achievements making the monoclonal antibody research back to life. After Royston, the co-founder of IDEC company and the main person in charge of research and development by Rituximab, left the San Diego. Out of the curiosity of history and the admiration of the predecessors, he has always wanted to see Royston, and finally the opportunity came. Every April, the world's antibody experts gather "the Athens of America" in Boston, discussing antibody engineering and drug research and development, called the "Protein Engineering Summit (PEGS). As a member of the the PEGS Scientific Advisory Board (SAB) in 2012, I served as the chairman of the meeting of the tumor antibodies, invited Royston to do the Keynote report of the General Assembly.

In 1981, Miller and Levy found one case suffering from follicular B-cell lymphoma can be cured with a murine anti-idiotype antibodies. Therefore, Royston established IDEC company specialized preparation of these personalized anti-idiotype antibody to each B-cell lymphoma patients. This may be the earliest "personalized medicine" of a bold attempt! Later, IDEC found the method is not economically feasible, but accidentally discovered the anti-CD20 "IDEC-C2B8" (Rituximab). They found that the antibody antigen in patients with B-cell lymphoma is not so serious actually. This phenomenon has also been confirmed in other antibody therapy for B-cell cancers. Furthermore, a later study gradually found that the reason why Rituximab is effective is associated with its many mechanism. The ADCC and CDC in it both have antibodies, but also it can induce tumor cell apoptosis. Royston also interestingly told about an interesting story of his early laboratory. That coincidence or even misunderstanding led to what may be the first time in human history with the fully human antibody treatment of cancer patients. For that reason, He also be interviewed on the U.S. national TV news. In short, whatever the adhere, coincidence, luck, or the final thrive after the studies of numerous laboratory, Rituxmab really opened up the road of the dream leading to tumor antibody treatment. Although this road is still long and difficult, we still need to give all out efforts to discover.

protein service

bmp 2

LIF